Glycoprotein changes in tumours: A renaissance in clinical applications

Clinical Science

Volumn 93, Issue 4, 1997, Pages 287-293

  Hounsell, Elizabeth F ^a   Young, Mia ^a,b   Davies, Michael J ^a,c  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b Skyehusapoleket I Fredrikstad   (Norway)

^c LONZA AG   (Switzerland)

Author keywords

Cancer; Carbohydrate tumour antigens; Magnetic resonance spectroscopy; Monoclonal antibody; Mucin; NMR spectroscopy

Indexed keywords

ANTIBODY; CELL SURFACE PROTEIN; GLYCOLIPID; GLYCOPROTEIN; GLYCOSYLTRANSFERASE; LECTIN; MONOSACCHARIDE; MUCIN; OLIGOSACCHARIDE; TUMOR ANTIGEN; TUMOR MARKER;

ANTIGEN BINDING; ANTIGEN EXPRESSION; BREAST TUMOR; CARBOHYDRATE ANALYSIS; CHROMATOGRAPHY; COLON CARCINOMA; GENE EXPRESSION; HUMAN; HUMAN CELL; LECTIN BINDING; MASS SPECTROMETRY; NUCLEAR MAGNETIC RESONANCE; PANCREAS CARCINOMA; PRIORITY JOURNAL; PROSTATE CARCINOMA; REVIEW; TUMOR CELL;

EID: 0030694884     PISSN: 01435221     EISSN: None     Source Type: Journal    
DOI: 10.1042/cs0930287     Document Type: Review

References (67)

1. Bhavanandan VP. Cancer-associated mucin and mucin-type glycoprotein. Glycobiology 1991; 1: 493-503.
2. Muramatsu T. Carbohydrate signals in metastasis and prognosis of human carcinomas. Glycobiology 1993; 3: 294-6.
3. Hounsell EF. Physicochemical analysis of oligosaccharide determinants of glycoproteins. Adv Carbohydr Chem Biochem 1994; 50: 311-50.
4. Hounsell EF, Davies MJ, Renouf DV. Studies of oligosaccharide and glycoprotein conformation. Biochem Soc Trans 1992; 20: 259-63.
5. 1H magnetic resonance spectroscopy. Int J Cancer 1994; 59: 248-61.
6. Mackinnon WB, Russel P, May GL, Mountford CE. Characterization of human ovarian epithelial tumors (ex vivo) by proton magnetic resonance spectroscopy. Int J Gynecol Cancer 1995; 5: 211-21.
7. Watkins WM. Biochemistry and genetics of the ABO Lewis and P blood group systems. Adv Hum Genet 1980; 10: 1-136, 379-85.
8. Hounsell EF, Davies MJ, Renouf DV. O-linked protein glycosylation structure and function. Glycoconjugate J 1996; 13: 19-26.
9. Feizi T. Demonstration by monoclonal antibodies that carbohydrate structures of glycoproteins and glycolipids are onco-developmental antigens. Nature (London) 1985; 314: 53-7.
10. Hakomori S. Glycosphingolipids. Sci Am. 1986; 254: 32-41.
11. Codington JF, Haavik S. Epiglycanin, a carcinoma-specific mucin-type glycoprotein of the mouse TA3 tumour. Glycobiol 1992; 2: 173-80.
12. Campbell JB, Finnie IA, Hounsell EF, Rhodes JA. Direct demonstration of increased expression of Thomsen-Friedenreich (TF) antigen in colonic adenocarcinoma and ulcerative colitis mucin and its concealment in normal mucin. J. Clin Invest 1995; 95: 571-6.
13. Hanski C, Hanisch FG, Riecken RO. Alteration of mucin-bound carbohydrate moieties in malignant transformation of colonic mucosa. Cancer J 1992; 5: 332-42.
14. Dahiya R, Kwak K-S, Byrd JC, Ho S, Yoon W-H, Kim YS. Mucin synthesis and secretion in various human epithelial cancer cell lines that express the MUC-I mucin gene. Cancer Res 1993; 53: 1437-43.
15. Starzynska T, Marsh PJ, Schofield PF, Roberts SA, Myers KA. Stern-PL prognostic significance of 5T4 oncofetal antigen expression in colorectal carcinoma. Br J Cancer 1994; 69: 899-902.
16. Davies MJ, Hounsell EF. Comparison of separation modes for high-performance liquid chromatography of glycoprotein- and proteoglycan-derived oligosaccharides. J Chromatogr 1996; 720: 227-34.
17. Yang J-M, Byrd JC, Siddiki BB, Chung Y-S, Okuno M, Sowa M, Kim YS, Matta KL, Brockhausen I. Alteration of O-glycan biosynthesis in human colon cancer tissues. Glycobiology 1994; 4: 873-84.
18. a oligosaccharide, but is distinct from NS 19-9 as to epitope recognition. J Biochem (Tokyo) 1988; 104: 817-21.
19. Solter D, Knowles BB. Monoclonal antibody defining a stage-specific mouse embryonic antigen (SSEA-1). Proc Natl Acad Sci USA 1978; 75: 5565-9.
20. Itzkowitz S. Carbohydrate changes in colon carcinoma. APMIS Suppl 1992; 27: 173-80.
21. Cleary KR, Ota DM, Hoff SD, Jrimura T. Monoclonal antibody defining a stage specific mouse embryonic antigen (SSAA-1). Matsushita Lab Invest 1990; 63: 780-91.
22. n antigen. Biochem Biophys Res Commun 1990; 170: 981-5.
23. Ryder SD, Smith JA, Rhodes JM. Peanut lectin: a mitogen for normal human colonic epithelium and human HT29 colorectal cancer cells. J Natl Cancer Inst 1992; 84: 1410-6.
24. Siddiki B, Ho JJL, Huang J, Bryd JC, Lau E, Yuan M, Kim YS. Monoclonal antibody directed against colon cancer mucin has high specificity for malignancy. Int J Cancer 1993; 54: 467-74.
25. Schumacher U, Higgs D, Loizidou M, Pickering R, Leathern A, Taylor I. Helix pomatia agglutinin binding is a useful prognostic indicator in colorectal carcinoma. Cancer 1994; 74: 3104-7.
26. Schwartz B, Bresalier RS, Kim YS. The role of mucin in colon cancer metastasis. Int J Cancer 1992; 50: 60-5.
27. n) in breast carcinogenesis. Virchows Arch 1995; 427: 251-8.
28. Brooks SA, Leatham, AJC. Expression of the CD15 antigen (Lewis x) in breast cancer. Histochemical J 1995; 27: 689-93.
29. Walker RA. Assessment of milk fat globule membrane antibodies and lectins as markers of short-term prognosis in breast cancer. Br J Cancer 1990; 62: 462-6.
30. Walker RA. Helix pomotio and prognosis of breast cancer. Br J Cancer 1993; 68: 453-4.
31. Brooks SA, Leathem AJC. Prediction of lymph node involvement in breast cancer by detection of altered glycosylation in primary tumour. The Lancet 1991; 338: 71-4.
32. Gusterson BA et al. Prognostic value of Helix pomotio in breast cancer. Br J Cancer, 1993; 68: 146-50.
33. Brooks SA, Leathem AJC. Expression of alpha-GalNAc glycoproteins by breast cancers. Br J Cancer 1995; 71: 1033-8.
34. Johnston WW, Szpak CA, Lottich SC, Thor A, Schlom J. Use of a monoclonal antibody (B72.3) as a novel immunohistochemical adjunct for the diagnosis of carcinomas in fine needle aspiration biopsy specimens. Human Pathol 1986; 17: 501-13.
35. Cohen AD, Gopas J, Karplus G, Cohen Y. CA15-3 mucin-like carcinoma-associated antigen and tissue polypeptide-specific antigen: correlation to disease state and prognosis in breast cancer patients. Isr J Med Sci 1995; 31: 155-9.
36. Pancino G, Osinaga E, Charpin C, Mistro D, Barque JPh, Roseto A. Purification and characterisation of a breast-cancer-associated glycoprotein not expressed in normal breast and identified by monoclonal antibody 83D4. Br J Cancer 1991; 63: 390-8.
37. Pal S, Sanyal U, Chattopadhyay U. Purification and characterization of a new 85-kDa glycoprotein antigen from human breast tumor. Int J Cancer 1995; 50: 759-65.
38. Chan DW, Beveridge RA, Bhargava, A, Wilcox PM, Kennedy J, Schwartz MK. Breast cancer marker CA549. Am J Clin Pathol 1994; 101: 465-70.
39. a, in combination with onco-developmental antigen. SSEA-1, recognised by two monoclonal antibodies to human milk-fat globule membranes. Biochem Biophys Res Commun 1985; 131: 543-50.
40. Devine PL, Clark BA, Birrell, GW, Layton GT, Ward BG, Alewood PF, McKenzie IFC. The breast tumour-associated epitope defined by monoclonal antibody 3EI.2 is an O-linked mucin carbohydrate containing N-glycolylneuraminic acid. Cancer Res 1991; 51: 5826-36.
41. Hanisch F-G, Stadie TRE, Peter-Katalinic J. MUCI glycoforms in breast cancer cell line T47D as a model for carcinoma-associated alterations of O-glycosylation. Eur J Biochem 1996; 236: 318-27.
42. Wright GL, Beckett ML, Lipford GB, Haley CL, Schellhammer PF. A novel prostate carcinoma-associated glycoprotein complex (PAC) recognized by monoclonal antibody TURP-27. Int J Cancer 1991; 47: 717-25.
43. Lipford GB, Wright GL Jr. Comparative study of monoclonal antibodies TURP-27 and HNK-I: their relationship to neural cell adhesion molecules and prostate tumor-associated antigens. Cancer Res 1991; 51: 2296-301.
44. Pastan I, Lovelace ET, Gallo MG, Rutherford AV, Magnani JL, Willingham MC. Characterization of monoclonal antibodies B1 and B3 that react with mucinous adenocarcinomas. Cancer Res 1991; 51: 3781-7.
45. Myers RB, Meredith RF, Schlom J, LoBuglio AF, Bueschen AJ, Wheeler RH, Stockard CR, Grizzle WE. Tumour associated glycoprotein-72 is highly expressed in prostatic adenocarcinomas. J Urol 1994; 152: 243-6.
46. Kim YD, Robinson DY, Manderino GL, Tribby HE, Tomita JT. Molecular characterization of the epitope in prostate and breast tumour-associated PR92 antigen. Cancer Res 1989; 49: 2379-82.
47. Sawabu N, Toya D, Takemori Y, Hattori N, Fukui M. Measurement of a pancreatic cancer-associated antigen (DUPAN-2) detected by a monoclonal antibody in sera of patients with digestive cancers. Int J Cancer 1986; 37: 693-6.
48. Wu JT, Chang J. Chromatographic characterization of CA19-9 molecules from cystic fibrosis and pancreatic carcinoma. J Clin Lab Anal 1992; 6: 209-15.
49. Ho JJL, Bi N, Yan P, Yuan M, Norton KA, Kim YS. Characterization of new pancreatic cancer-relative monoclonal antibodies directed against purified mucin. Cancer Res 1991; 51: 372-80.
50. a/type I chain-related antigen on carcinoma-associated mucins. Biol Chem 1993; 374: 1083-91.
51. Martersteck CM, Kedersha NL, Drapp DA, Tsui TG, Colley KJ. Unique alpha2-8-sialylated glycoproteins in breast cancer and leukemia cells. Glycobiology 1996; 6: 289-301
52. Schellhammer PF, Wright GL. Biomolecular and clinical characteristics of PSA and other candidate prostate tumour markers. Urol Clin North Am 1993; 20: 597-606.
53. Armbuster DA. Prostate specific antigen: biochemistry, analytical methods and clinical applications. Clin Chem 1993; 39: 181-95
54. Hanski C, Hanski M-L, Zimmer T, Ogorek D, Devine P, Riecken E-O. Characterization of the major sialyl-Lex-positive mucins present in colon, colon carcinoma, and sera of patients with colorectal cancer. Cancer Res 1995; 55: 928-33.
55. Mannori G, Crottet P, Cecconi O, Hanasaki K, Aruffo A, Nelson RM, Varki A, Bevilacqua MP. Differential colon cancer cell adhesion to E-, P-, and I-selectin: role of mucin-type glycoproteins. Cancer Res 1995; 55: 4425-31.
56. Fukuda, M. Possible roles of tumour-associated carbohydrate antigens. Cancer Res 1996; 56: 2237-44.
57. Levesque M, D'Costa Yu H, Tadross Diamondis EP. Immunoreactive prostate-specific antigen in lung tumors. J Clin Lab Anal 1995; 9: 375-9
58. Devine PL, McGuckin MA, Ramm LE, Ward BG, Pee D, Long S. Serum mucin antigens CASA and MSA in tumours of the breast, ovary, lung, pancreas, bladder, colon and prostate. Cancer 1993; 72: 2007-15.
59. Yu C-J, Yang P-C, Shew J-Y, Hong T-M, Yang S-C, Lee Y-C, Lee, L-N, Luh K-T, Wu C-W. Mucin mRNA expression in lung adenocarcinoma cell lines and tissues. Oncology 1996; 53: 118-26.
60. Kim YS, Gum J, Brockhausen I. Mucin glycoproteins in neoplasia. Glycoconjugate J 1996; 13: 693-707.
61. Yadema KA, Kenemans P, Wobbes T, van Kamp GJ, de Bruijn HW, Thomas CM, Massuger LF, Schijl CP, Bon GG, Vermorken JB, Voorhorst F, Hilgers JO. Carcinoma-associated mucin serum markers CAM26 and CAM29: efficacy in detecting and monitoring patients with cancer of the breast, colon, ovary, endometrium and cervix. Int J Cancer 1991; 47: 170-9.
62. 1H NMR in the structural and conformational analysis of oligosaccharides and glycoconjugates. Progr NMR Spectrosc. 1995; 27: 445-74
63. n antigen mediate inhibition of natural killer cell cytoxicity. Cancer Res 1996; 52: 4741-6.
64. n. Cancer Res 1992; 52: 5663-7.
65. Rughetti A, Turchi V, Appollonj C, Scambia G, Panici PB, Roncucci G, Mancuso S, Frati L, Nuti M. Human B-cell immune response to the polymorphic epithelial mucin. Cancer Res 1993; 53: 2457-9.
66. Vitetta ES, Uhr JW. Monoclonal antibodies as agonists: an expanded role for their use in cancer therapy. Cancer Res 1994; 54: 5301-9.
67. Peterson JA, Couto JR, Taylor MR, Ceriani RL. Selection of tumour-specfic epitopes on target antigens for radioimmunotherapy of breast cancer. Cancer Res 1995; 55: 5847-51.